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Abstract
Tissue-type transglutaminase (tTG, EC 2.3.2.13) has been
implicated in various disease paradigms including neurode-
generative disease. In these studies, tTG induction after
traumatic brain injury was studied using a rat cortical impact
model. Using western blots, two forms of tTG protein
expression were identified ± a 79-kDa primary form (tTG-L)
and a less abundant 70-kDa form (tTG-S). Both forms of tTG
protein were elevated after injury. In ipsilateral cortex, peak
induction of tTG-L protein [561%  80% of control (n  5)]
was observed five days after injury, with expression remaining
elevated after two weeks. Peak induction of tTG-S protein
[302%  81% of control (n  5)] was observed three days
after injury. Lesser tTG protein induction was observed in
hippocampus. Northern blot analysis demonstrated two tTG
transcripts in the ipsilateral cortex with peak induction of tTG-L
mRNA three days after injury. However, tTG-S mRNA was not
identified in control samples and only faintly detected in
injured tissue. To facilitate analysis of low abundance
transcripts in smaller tissue samples, a semiquantitative real-
time PCR strategy was used. Semi-quantitative PCR analysis
of tTG-L mRNA induction in ipsilateral cortex (peak after three
days; 414%  21% of control, n  3) confirmed tTG-L mRNA
induction determined by northern blot (410% of control).
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Tissue-type transglutaminase (type II transglutaminase, trans-
glutaminaseC,tTG)hasbeenimplicatedandmayplayarolein
apoptotic cell death, neurodegenerative disease and in protein
aggregation associated with neurodegenerative disease.
Although apoptosis is a prominent feature of cell death
following TBI and TBI, it is a risk factor for a number of
neurodegenerative diseases, such as Alzheimer's disease, no
studies have examined the alteration in tTG following CNS
injury (CNS).
tTG is a Ca
2+ dependent enzymeand is a member of a
family of transglutaminases (TG) that catalyzes the
transamidation of glutamine residues. tTG can catalyze the
incorporation of a polyamine into a polypeptide-bound
glutamine leading to the formation of a (c-glutamyl)
polyamine bond. Alternatively, when this reaction occurs
between the c-carboxamide group of a peptide-bound
glutamine residue and the e-amino group of a peptide-bound
lysine residue, e-(c-glutamyl) lysine isopeptide bond is
formed (Greenberg et al. 1991). This isopeptide bond is
resistant to proteolytic cleavage, and may serve not only to
stabilize proteins against degradation, but also to alter their
function. There are numerous substrates for tTG, including
structural proteins, enzymes, and elements of signal trans-
duction pathways (Chen and Mehta 1999).
Though there are currently seven known TGs, only TG 1
(106 kDa), tTG (80 kDa) and TG 3 (77 kDa) have been
identified within the brain (Selkoe et al. 1982). Importantly,
Kim et al. (1999) revealed that only TG 1 and tTG were
expressed within the cerebral cortex, with tTG most abun-
dantly expressed.
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Gah, that interacts with phospholipase C-d1 (Nakaoka et al.
1994; Feng et al. 1996; Park et al. 1998). Gah was originally
identified as the signal transducer between epinephrine
binding to a1-adrenoreceptor and phospholipase C (PLC)
activation (Im et al. 1990; Im and Graham 1990; Das et al.
1993), specifically PLC-d1 (Feng et al. 1996). The identity
of Gah as tTG was clarified by peptide foot-print analysis
between tTG and Gah and cross-reactivity between antibod-
ies for rat liver Gah and antibodies for guinea pig liver tTG
(Nakaoka et al. 1994). The C-terminal region of tTG is
important for its ability to interact with PLC (Hwang et al.
1995; Feng et al. 1996) and with receptor molecules (Feng
et al. 1999).
Previous reports have described changes in over all TG
activity during the development of mouse brain (Maccioni
and Seeds 1986) and rat brain (Gilad and Varon 1985; Perry
and Haynes 1993). Other proposed functions include
involvement in cell±matrix interactions, wound healing,
regeneration and neurodegenerative disease (for a review
see Lesort et al. 2000). Among its many possible functions,
tTG has been implicated as a mediator of apoptosis. In the
neuroblastoma cell line SK-N-BE(2), tTG overexpression
stimulated apoptosis while inhibition of tTG expression with
an antisense construct decreased both spontaneous and
retinoic acid-induced apoptosis (Melino et al. 1994). tTG-
mediated apoptosis may involve multiple target substrates.
During apoptosis tTG modifies several proteins including
histone protein (Ballestar et al. 1996), actin (Nemes et al.
1997), troponin (Gorza et al. 1997), and retinoblastoma
protein (Oliverio et al. 1997). Given the complexity with
which tTG interacts with numerous proteins, the role of tTG
in apoptosis is not yet understood (for a review see Melino
and Piacentini 1998).
tTG mRNA and protein expression have been demon-
strated in cultured astrocytes from two-day postnatal rats
(Monsonego et al. 1997). In astrocyte cultures treated with
IL-1b, two transcripts encoding tTG were identified ± a full-
length long form (encoding a 77-kDa protein), and a less
abundant short form (encoding a 73-kDa protein) that
lacked a portion of the C-terminus coding region and had a
truncated 3¢ untranslated region. Interestingly, the enzymatic
activity of the tTG short form lacked the GTP-dependence
observed in the tTG long form (Monsonego et al. 1997). The
functional significance of the two types of tTG expressed in
cultured astrocytes is not yet clear.
Induction of tTG expression by IL-1b and TNF-a in vitro
may prove relevant to the in vivo response to traumatic
injury. Traumatic brain injury (TBI) induces the expression
of both IL-1b and TNF-a (Woodroofe et al. 1991; Taupin
et al. 1993; Rostworowski et al. 1997; Herx et al. 2000).
Using a microdialysis probe to induce mechanical trauma as
well as measure cytokine levels, Woodroofe et al. (1991)
showed a 15-fold induction of IL-1 within a two-day period.
Using a fluid percussion model of traumatic brain injury,
Taupin et al. (1993) demonstrated IL-1 induction in cortex
and hippocampus up to 18 h after injury and TNF-a
induction 3±8 h after injury. After stab injury, IL-1b mRNA
is induced 3±12 h after injury, while TNF-a mRNA is
induced from 3 to 96 h after injury (Rostworowski et al.
1997). After corticectomy, both IL-1b and TNF-a transcripts
were increased three hours after injury (Herx et al. 2000).
If injury-induced IL-1b and TNF-a elevate tTG expression
in vivo as has been shown for in vitro astrocytes, then tTG
may play a role in the subsequent CNS response to trauma.
In particular, the pro-apoptotic effects of tTG expression may
contribute to the post-traumatic apoptotic phenotype seen in
CNS injury. The apoptotic components of cell death after
experimental TBI have been examined in models of fluid
compression (Rink et al. 1995; Yakovlev et al. 1997; Conti
et al. 1998) and cortical impact (Colicos and Dash 1996;
Newcomb et al. 1999).
The aim of this study was to determine whether tTG is
up-regulated as a result of TBI, and if so, to determine the
time course of induction. Using western blot analyses, we
found that both forms of tTG [tTG-L (79 kDa) and tTG-S
(70 kDa)] were strongly induced in ipsilateral cortex after
traumatic injury with predominant expression of tTG-L.
These two forms are similar to the long and short forms seen
in cytokine-induced astrocytes (Monsonego et al. 1997). To
further analyze this phenomenon, induction of specific tTG
transcripts was verified by northern blot and semiquantitative
PCR analysis.
Materials and methods
Surgical preparation and controlled cortical impact
traumatic brain injury
A previously described cortical impact injury device was used to
produce TBI in adult rats (Dixon et al. 1991; Pike et al. 1998).
Cortical impact TBI results in cortical deformation within the
vicinity of the impactor tip associated with contusion, and neuronal
and axonal damage that is constrained in the hemisphere ipsilateral
to the site of injury (Gennarelli 1994; Meaney et al. 1994). Adult
male (280±300 g) Sprague±Dawley rats (Harlan, Indianapolis, IN,
USA) were anesthetized with 4% isoflurane in a carrier gas of 1 : 1
O2/N2O (4 min) followed by maintenance anesthesia of 2.5%
isoflurane in the same carrier gas. Core body temperature was
monitored continuously by a rectal thermistor probe and maintained
at 37° 1 °C by placing an adjustable temperature controlled
heating pad beneath the rats. Animals were mounted in a stereotactic
frame in a prone position and secured by ear and incisor bars. A
midline cranial incision was made, the soft tissues were reflected,
and a unilateral (ipsilateral to site of impact) craniotomy (7 mm
diameter) was performed adjacent to the central suture, midway
between bregma and lambda. The dura mater was kept intact over
the cortex. Brain trauma was produced by impacting the right cortex
(ipsilateral cortex) with a 5-mm diameter aluminum impactor tip
(housed in a pneumatic cylinder) at a velocity of 3.5 m/s with a
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tion). Velocity was controlled by adjusting the pressure (compressed
N2) supplied to the pneumatic cylinder. Velocity and dwell time
were measured by a linear velocity displacement transducer (Lucas
Shaevitz
TM model 500 HR, Detroit, MI, USA) that produces an
analogue signal that was recorded by a storage-trace oscilloscope
(BK Precision, model 2522B, Placentia, CA, USA). Sham-injured
animals underwent identical surgical procedures but did not receive
an impact injury. Appropriate pre- and post-injury management was
maintained and these measures complied with all guidelines set forth
by the University of Florida Institutional Animal Care and Use
Committee and the National Institutes of Health guidelines detailed
in the Guide for the Care and Use of Laboratory Animals.
Tissue lysis and protein purification
Cortical and hippocampal tissues were collected from animals at
1±14 days after sham-injury or TBI. At the appropriate time-points,
TBI or sham-injured animals were killed with CO2 and subsequent
decapitation. Ipsilateral and contralateral (to the impact site) cortices
and hippocampi were rapidly dissected and snap-frozen in liquid
nitrogen. Tissue samples were stored at )80°C. Cortices were
homogenized in a glass tube with a Teflon dounce pestle in 15
volumes of ice-cold triple detergent lysis buffer (20 mM HEPES,
1m M EDTA, 2 mM EGTA, 150 mM NaCl, 0.1% SDS, 1.0%
IGEPAL 40, 0.5% deoxycholic acid, pH 7.5) containing a broad
range protease inhibitor cocktail (cat. no. 1-836-14; Roche Molec-
ular Biochemicals, Indianapolis, IN, USA). Samples were sonicated
and centrifuged at 800 g for 5 min at 4°C. The supernatant was then
collected for western blot analysis.
Western blot analysis
Protein concentrations of tissue homogenates were determined by
bicinchoninic acid microprotein assays (Pierce Inc., Rockford, IL,
USA) with albumin standards. 20 lg aliquots of each sample were
prepared for sodium dodecyl sulfate±polyacrylamide gel electro-
phoresis (SDS±PAGE) by addition of 2´ loading buffer (1´
loading buffer contains 125 mM Tris-HCl (pH 6.8), 100 mM DTT,
4% SDS, 0.01% bromophenol blue, and 10% glycerol). Samples
with loading buffer were heated for 10 min at 100°C, centrifuged
for 1 minute at 10 000 g, and were resolved by SDS±PAGE on
7.5% Tris/glycine gels at 200 V for 1 h at 4°C. Following
electrophoresis, fractionated proteins were transferred to Immobi-
lon-p polyvinylidene fluoride (PVDF) membrane (Millipore,
Bedford, MA, USA) in a transfer buffer containing 192 mM
glycine, 25 mM Tris-HCl (pH 8.3), and 10% methanol at 100 V
for 1 h at 4°C. Ponceau Red (Sigma, St Louis, MO, USA) was
used to stain membranes to confirm successful transfer of protein
and to insure that an equal amount of protein was loaded in each
lane. Blots were blocked for 1 h at room temperature in 5%
non-fat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, and
0.005% Tween-20, pH 7.5).
Immunoblots were probed with one of two monoclonal anti-tTG
antibodies, designated CUB 7402 or TG100 (LabVision, Fremont,
CA, USA). Following overnight incubation at 4°C with the primary
antibody (1 : 3000), blots were incubated for 1 h at room
temperature (22°C) in 3% non-fat milk/TBST containing a horse-
radish peroxidase-conjugated goat anti-mouse IgG (1 : 3000; Bio-
Rad, Hercules, CA, USA). Bound antibodies were visualized with
enhanced chemiluminescence (ECL; Amersham, Piscataway, NJ,
USA) on Kodak Biomax ML chemiluminescent film.
RNA purification
Total RNAwas isolated from control and injured samples of cortical
or hippocampal tissue using TRIzol reagent (Gibco BRL, Rockville,
MD, USA), isopropanol precipitation, and ethanol washes according
to the manufacturer's instructions. Samples were resuspended in 50±
100 lL DEPC-treated water.
Reverse transcription
Total RNA (3 lg) was incubated with 1 lL oligo(dT) (0.5 mg/mL,
Gibco BRL) at 70°C for 10 min, then at 4°C for five minutes. A
reverse transcription reaction mixture was then added to the RNA-
oligo(dT) sample for a final volume of 20 lL, containing 20 mM
Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl2, 500 lM dNTP's,
10 mM DTT, 50 units SuperScript II reverse transcriptase (Gibco
BRL) and 40 units RNaseOUT recombinant ribonuclease inhibitor
(Gibco BRL). The sample was incubated at 42°C for 55 min, 70°C
for 15 min for enzyme denaturation, and then transferred to 4°C.
Each sample was diluted to a final volume of 100 lL with DEPC-
treated water.
Primer selection
TTG-specific primers
All base pair designations refer to GeneBank locus AF106325, rat
tissue-type transglutaminase (TGaseII). 5¢TG (actttgacgtgtttgcccac;
bp 1470±1489) recognizes an upstream homologous sequence in
tTG-L and tTG-S transcripts. 3¢tTG-L (caatatcagtcgggaacaggtc; bp
1961±82) recognizes a downstream tTG-L mRNA-specific
sequence. 3¢tTG-S (gctgagtctgggtgaagacacag; bp 1861±1872 and
2083±93) recognizes a downstream tTG-S mRNA-specific
sequence. 3¢tTG-S primer bridges the junction created absence of
bp 1873±2082 (a sequence present exclusively in tTG-L). The
underlined 3¢ half of the 3¢tTG-S sequence will hybridize to both
tTG-L- and tTG-S-specific sequence, while the full length primer
will hybridize only to tTG-S mRNA sequence.
GAPDH-specific primers
All base pair designations for GAPDH-specific primers refer to
GeneBank locus AF106860. The upstream primer is designated
5¢GPD (ggctgccttctcttgtgac; bp 903±921) and the downstream
primer is designated 3¢GPD (ggccgcctgcttcaccac; bp 1624±1641).
Standard PCR
A PCR reaction buffer was added to 2 lL of reverse transcription
product for a final volume of 25 lL containing 20 mM Tris-HCl
(pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 200 lM dNTP's, 0.5 lM
dNTP's, 6% DMSO, 1.25 units Taq DNA polymerase (Gibco BRL).
The mixture was then transferred to a PCR apparatus for
amplification: each denaturation, annealing, and extension step
was held for 30 s (two cycles of 95°,6 5 °C, and 72°C; then two
cycles of 95°C, 62.5°C, and 72°C; then 32 cycles of 95°C, 60°C,
and 72°C). Aliquots of PCR products were loaded onto 1.5%
agarose gels and separated by electrophoresis in TAE buffer (40 mM
Tris-acetate, 1 mM EDTA, pH 7.5) containing 5 lg/mL ethidium
bromide. To assay for genomic DNA contamination, RNA samples
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Any samples showing genomic contamination underwent repurifi-
cation and repeat assay for genomic contamination prior to PCR
analysis for transcript expression.
Northern blot analysis
Total RNA (10 lg) was size-fractionated by electrophoresis in 1.5%
agarose gels containing 6% formaldehyde, then transferred onto
Hybond N + nylon membrane (Amersham), and fixed by baking at
80°C for 1 h under vacuum. Membranes were hybridized in a
solution containing 5´ SSPE (1´ SSPE contains 180 mM NaCl,
10 mM sodium phosphate, and 1 mM EDTA, pH 7.7), 5´ Denhardt's
solution (1´ Denhardt's solution contains 0.02% bovine serum
albumin, 0.02% Ficoll, and 0.02% polyvinylpyrrolidone), 0.5%
SDS, 20 lg/mL sheared denatured salmon sperm DNA, and random
primer-generated probe at 65°C overnight. DNA probes were
radiolabeled to a specific activity of 1 ´ 10
9 dpm/lg by random-
primed labeling (Gibco BRL) with [a-
32P]dCTP (3000 Ci/mmol;
DuPont NEN, Boston, MA, USA). After hybridization, membranes
were washed sequentially with 2´ SSPE/0.1% SDS at room
temperature, then 1´ SSPE/0.1% SDS at 65°C, and then 0.1´
SSPE/0.1% SDS at 65°C. Membranes were exposed to film with
one intensifying screen at )80°C.
TTG and GAPDH cDNA
For northern blot analysis of tTG expression, a 414-bp tTG-cDNA
was generated via PCR. This fragment corresponds to 403 bp of
tTG-L coding sequence and to 414 bp of tTG-S coding sequence. To
monitor GAPDH expression, a 1.2-kb EcoRI fragment from
HHCMC32 (American Type Culture Collection, Manassas, VA,
USA) was used.
Semi-quantitative/light cycler PCR
Real time PCR was performed using a Light Cycler rapid thermal
cycler system (Roche Diagnostics, Indianapolis, IN, USA) according
to the manufacturer's instructions. Reactions were performed in a
10 lL volume with 0.5 lM primers, 2.5 mM MgCl2. Other reagents
including nucleotides, FastStart Taq DNA polymerase, and buffer
were used as provided in the LightCycler-FastStart DNA Master
SYBR Green I reaction mix (Roche Diagnostics). Amplification
protocol included a 5 minute 95°C denaturation; one cycle with 95°C
denaturation for 5 s, 65°C annealing for 10 s, and 72°C extension for
35 s; one cycle with 95°C denaturation for 5 s, 62.5°C annealing for
10 s, and 72°C extension for 35 s; then 30±40 cycles of 95°C
denaturation for 5 s, 60°C annealing for 10 s, and 72°C extension for
35 s. Detection of the fluorescent product occurred at the end of the
72°C extension periods. Specificity of the amplification product from
each primer pair was confirmed by melting curve analysis of the PCR
product and subsequent gel electrophoresis.
Quantification was performed by online monitoring for identifi-
cation of the exact time point at which the logarithmic linear phase
could be distinguished from the background (crossing point). The
crossing point is expressed as a cycle number.
Standard curve preparation and semiquantitative
PCR analysis
From the northern blot analysis, maximal tTG-L and tTG-S mRNA
expression was identified three days after injury. The reverse
transcription product from ipsilateral cortical RNA collected three
days after injury underwent serial dilution, creating a standard curve
of 100%, 33%, 11% and 3.7% of original RT product. Each dilution
from the standard curve was analyzed with the LightCycler PCR
using primer sets for tTG-L, tTG-S, or GAPDH mRNA. For each
primer set, a crossing point cycle number was determined for each
dilution of the standard curve. Linear regression analysis of the
logarithm of the dilution factor vs. the crossing point cycle number
generated a standard curve for each transcript-specific primer set.
From each primer set's standard curve, a crossing point cycle
number could be converted to a relative amount of RNA.
For individual samples, the crossing point cycle number was
identified with the LightCycler PCR. Then, using the standard curve
for each primer set, the amount of tTG-L, tTG-S, or GAPDH mRNA
was determined. The amount of each transcript in sham animals was
set at 100%, and the level of expression in an experimental sample
was calculated as a percentage of sham expression.
Statistical analyses
For the western and northern blots, semiquantitative analysis was
performed by computer-assisted densitometric scanning (AlphaIm-
ager 2000 Digital Imaging System, San Leandro, CA, USA). Data
were acquired as integrated densitometric values and transformed to
percentages of the densitometric levels obtained from sham-injured
animals visualized on the same blot. PCR data was evaluated by
least squares linear regression followed by ANOVA and Dunnett's
multiple comparison test. All values are given as mean  SEM.
Differences were considered significant if p < 0.05.
Results
Western blot analysis of tTG expression in cortex
after traumatic injury
Total protein was prepared from rat ipsilateral cortex after
cortical impact injury. Expression of tTG was examined
using two monoclonal anti-tTG antibodies, TG-100 and
CUB-7402. Figure 1(a) shows western blot analyses for tTG
expression in rat ipsilateral cortex one to 14 days after injury.
Using the TG-100 antibody, two distinct tTG protein bands
were identified: a 79-kDa band corresponding to the tTG
long form (tTG-L) and a 70-kDa band that may represent
the tTG short form (tTG-S). The presence of tTG-S was not
detected with the CUB-7402 antibody; however, with
prolonged film exposure of the TG-100 blots, tTG-S was
more clearly identified (Fig. 1b).
Western blot analyses of ipsilateral cortex samples using
TG-100 were quantified by densitometric analysis (Fig. 1c).
Levels of tTG-L and tTG-S were expressed as percentage of
sham levels. Sham-operated animals showed no change in
tTG-L or tTG-S expression one day and five days after
craniotomy (Fig. 1a). tTG-L induction was observed
1±14 days after cortical injury. tTG-L expression peaked at
561%  16% (n  5) five days after injury, with statistically
significant elevated expression at 3±14 days. tTG-S induc-
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expression (302%  81%, n  5) at three days. However,
levels of tTG-S induction did not reach statistical signifi-
cance (Fig. 1c). No changes in tTG-L or tTG-S expression
were observed in the contralateral cortex (not shown).
Western blot analysis of tTG expression
in hippocampus after traumatic injury
Total protein was prepared from rat ipsilateral hippocampus
after cortical impact injury. Expression of tTG was examined
using TG-100 and CUB-7402 antibodies. Figure 2(a) shows
western blot analyses for tTG expression in rat ipsilateral
hippocampus one to 14 days after injury. Compared to
ipsilateral cortex, lower levels of tTG induction were
identified in the hippocampus, and tTG-S was not detected
with either antibody. Quantitative densitometric analysis of
tTG-L expression revealed peak levels (194%  9%, n  5)
five days after injury. Increased tTG-L expression was
observed 1±14 days after injury, but statistically significant
increases were only detected five days after injury (Fig. 2b).
tTG transcript PCR analysis
Given the previous report of two types of tTG expressed in
rat brain astrocytes (Monsonego et al. 1997), and the current
findings suggesting long (tTG-L) and short (tTG-S) forms of
tTG in ipsilateral rat cortex after injury, the molecular
analysis of tTG transcripts was performed. Figure 3(a)
provides a schematic diagram of the two tTG transcripts
previously described (Monsonego et al. 1997). The tTG-L
transcript contains an additional 209 bp sequence (bp 1873±
2082) absent in tTG-S mRNA. To investigate which tTG
transcripts were expressed after injury, total RNA was
purified from rat ipsilateral cortex five days after injury.
The sample was then reverse transcribed and underwent
standard PCR to detect tTG-L, tTG-S and GAPDH tran-
scripts. Figure 3(b) shows the results of the PCR analysis,
indicating the presence of both tTG-L and tTG-S mRNA in
rat ipsilateral cortex five days after injury. The identity of the
Fig. 1 Western blot analysis for tTG expression in ipsilateral cortical
protein samples using the anti-TG-II antibodies TG-100 and CUB-
7402. (a) Samples were collected from sham-operated animals one
and ®ve days after surgery (S1, S5) as well as from injured animals
from one day to 14 days after injury (1d)14d). (b) Longer exposure of
the western blot using TG-100 antibody suggests co-expression of
tTG-L (79 kDa, full length tTG) and tTG-S (70 kDa, a short form
of tTG). (c) Quantitative analysis: western blot analyses using TG-100
antibody were quanti®ed by densitometry, and the level of tTG (tTG-L
and tTG-S) expression in the ipsilateral cortex of injured animals was
calculated as a percentage of sham (control) tTG expression. For each
condition, n  5 animals. One-way ANOVA was performed, followed by
Dunnett's multiple comparison test to evaluate statistical signi®cance.
Comparing tTG-L expression from injured animals to control/sham
animals, increased levels of expression were statistically signi®cant at
three, ®ve, seven, and 14 days (*p < 0.05, **p < 0.01). Comparing
tTG-S expression from injured animals to control/sham animals,
increased levels of expression were not statistically signi®cant.
Fig. 2 Western blot analysis for tTG expression in ipsilateral hippo-
campal protein samples using the anti-tTG antibodies TG-100 and
CUB-7402. Samples were collected from sham-operated animals one
day and ®ve days after surgery (S1, S5) as well as from injured ani-
mals one day to 14 days after injury (1d-14d). tTG-S, the shorter form
of tTG (70 kDa), was not identi®ed in these samples even at longer
exposures. (b) Quantitative analysis: western blot analyses using
TG-100 were quanti®ed by densitometry, and the level of tTG
expression in the ipsilateral hippocampus of injured animals was
calculated as a percentage of sham (control) tTG expression. Only
tTG-L was quanti®ed, as tTG-S expression was not identi®ed in every
sample. For each condition, n  5 animals. One-way ANOVA was
performed, followed by Dunnett's multiple comparison test to evaluate
statistical signi®cance. Comparing tTG-L expression from injured
animals to control/sham animals, increased levels of expression were
statistically signi®cant at ®ve days (*p < 0.05).
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analysis (not shown).
Northern blot analysis of ipsilateral cortex
RNA postinjury
Given the observation of both tTG-L and tTG-S transcripts in
ipsilateral cortex after injury by PCR, northern blot analysis
was performed to assess the temporal profile of tTG
induction (Fig. 4a). Under sham conditions tTG-L mRNA
was barely detectable. tTG-L mRNA expression was elevated
1±5 days after injury, with maximal tTG-L transcript
expression (410% of sham expression) observed three days
after injury. The northern blot analysis of tTG-L expression
in ipsilateral cortex samples was quantified by densitometry
and total RNA loading was corrected using GAPDH
expression (Fig. 4b). Although maximal tTG-S transcript
expression was also observed three days after injury, the
degree of induction cannot be calculated, as tTG-S mRNA
was undetectable under sham conditions.
Northern blot analysis was able to demonstrate the
temporal profile of tTG-L transcript induction in response
to cortical injury. However, clear identification and analysis
of tTG-S transcript was not possible due to background
signal on the northern blots, as well as the low levels of
tTG-S transcript expression. To address these limitations, a
semiquantitative PCR strategy was developed to indepen-
dently measure tTG-L and tTG-S transcript levels. This
approach has two major advantages: (1) PCR amplification
allows for detection of much lower levels of transcript
expression and (2) a PCR-based approach decreases the
amount of total RNA required for analysis, thereby facilitat-
ing analysis of smaller tissue samples and obviating the need
to pool RNA samples prior to analysis.
Standard curve generation for semiquantitative PCR
using serially diluted cDNA
As the highest level of tTG-L and tTG-S transcript expres-
sion was observed in ipsilateral cortex three days after injury,
ipsilateral cortex total RNA was collected three days after
injury, reverse transcribed, and serially diluted to generate a
standard curve of relative amounts of RNA. These samples
underwent analysis using the LightCycler PCR with primer
sets for tTG-L, tTG-S, or GAPDH mRNA. For each dilution
sample (100%, 33.3%, 11.1% and 3.7%), the PCR analysis
yielded a crossing point cycle number for each primer pair
(tTG-L, tTG-S or GAPDH-specific). Figure 5 shows the
linear regression analysis of each primer set's crossing point
cycle number vs. the logarithm of the dilution factor. For
Fig. 3 (a) Schematic diagram of tTG transcripts. tTG-L mRNA
contains an additional sequence (bp 1873±2082) not present in tTG-S
mRNA. This sequence encodes additional coding region and 3¢
untranslated region. PCR primer sites are designated: 5¢TG (bp 1470±
1489) recognizes homologous sequence in tTG-L and tTG-S
transcripts. 3¢TG-L (bp 1961±82) recognizes tTG-L mRNA-speci®c
sequence. 3¢TG-S recognizes the junctional sequence created by the
absence of the tTG-L-speci®c sequence (bp 1861±1872 and 2083±
93). All base pair designations refer to GeneBank locus AF106325, rat
tissue-type transglutaminase (TGaseII). (b) PCR analysis of ipsilateral
cortex RNA. GPD, 739 bp PCR product generated with rat GAPDH-
speci®c primers. (5¢GAPDH primer includes bp 903±921; 3¢GAPDH
primer includes bp 1624±1641, as designated in GeneBank locus
AF106860). tTG-L, 513 bp PCR product generated with tTG-L-speci®c
primers. tTG-S, 414 bp PCR product generated with tTG-S-speci®c
primers.
Fig. 4 Northern blot analysis of ipsilateral cortex RNA after injury. (a)
Above: northern blot using tTG-S PCR product as template for random
hexamer-generated probe. Positions of tTG-L mRNA (3.7 kb) and
tTG-S mRNA (2.4 kb) are noted. Below: northern blot using GAPDH
cDNA as template for random hexamer-generated probe. Position of
GAPDH (2 kb) mRNA is noted. (b) Northern blot analysis for tTG-L
mRNA expression (e) were quanti®ed by densitometry and corrected
for loading by the level of GAPDH expression. tTG-L mRNA expres-
sion is represented as a percentage of sham expression. For each
condition, tissue from three replicate animals was combined prior to
northern analysis.
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required to cover the serially diluted standard curve varied:
11±18 cycles for GAPDH, 20±26 cycles for tTG-L, 29±35
cycles for tTG-S. These differences reflect primarily the
abundance of the transcripts. GAPDH mRNA is the most
abundant transcript and requires the fewest cycles, whereas
tTG-S mRNA is the least abundant transcript and requires the
most cycles. Furthermore, each primer set amplified its target
transcript with different efficiencies (GAPDH 79%, tTG-L
80%, and tTG-S 90%).
Semi-quantitative PCR analysis of experimental
samples
Experimental RNA samples were analyzed with the Light-
Cycler PCR system, generating crossing point cycle numbers
for tTG-L-, tTG-S- and GAPDH-specific primers. Using the
standard curves, the crossing point cycle numbers were
converted to relative amounts of RNA. These relative
amounts were then expressed as percentage of control/sham
levels. Figure 6 shows the time course of tTG-L and tTG-S
RNA expression in ipsilateral cortex and hippocampus after
cortical injury. In cortex, maximal tTG-L mRNA expression
was observed (414%  21% (n  3) of control) three days
after injury, while maximal tTG-S mRNA expression was
observed [369%  28% (n  3) of control] two days after
injury. In hippocampus, maximal tTG-L and tTG-S mRNA
levels were observed one day after injury, 196%  14%
(n  3) of control, and 201%  16% (n  3) of control,
respectively.
Linear regression analysis of tTG-L mRNA
quantification by PCR versus northern blot
To verify that semiquantitative PCR methods would yield
results similar to northern blot analysis, a linear regression
analysis was performed to compare tTG-L mRNA expression
determined by PCR and northern blot (Fig. 7). Results from
northern blot and PCR analyses fit a linear correlation with a
slope  1.01, r
2  0.95. This comparison is unavailable for
Fig. 5 Standard curve generation for tTG-L-, tTG-S-, and GAPDH-
speci®c quantitative PCR. Total RNA was extracted from rat ipsilateral
cortical tissue three days after injury. RNA samples were reverse
transcribed, and then the cDNA's were serially diluted. Aliquots of the
cDNA dilution curve underwent real-time PCR using primer pairs for
tTG-L mRNA, tTG-S mRNA, or GAPDH mRNA. For each dilution and
each primer set, the cycle number at which the PCR ampli®cation
entered the log-linear region was identi®ed (crossing point cycle
number). Standard curves were generated by plotting the log con-
centration of total RNA versus the crossing point cycle number, and
a linear regression analysis was performed (r
2 ranged from 0.980 to
0.998). For quantitation, individual sham and experimental RNA
samples underwent real time PCR, generating a crossing point cycle
number for each primer set. Using the standard curves, the cycle
number was converted to an amount of RNA. These amounts were
then expressed as percentage of control/sham RNA.
Fig. 6 Semi-quantitative PCR analysis of tTG-L and tTG-S mRNA
expression in cortex (a) and hippocampus (b). tTG-L (e) and tTG-S (n)
mRNA levels are expressed as a percentage of control/sham animal
expression. One-way anova was performed, followed by Dunnett's
multiplecomparisontest,toevaluatestatisticalsigni®cance.Comparing
tTG-L mRNA expression from injured animals to control/sham animals.
*p <0.05; **p <0.01. Comparing tTG-S mRNA expression from injured
animals to control/sham animals. #p <0.05; ##p <0.01.
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on the northern blot.
Discussion
This study describes the increased expression of tTG in
cortex and hippocampus after traumatic brain injury. Two
forms of tTG were expressed, tTG-L and tTG-S, that differ in
their C-terminal regions. Western blot analysis with two
separate antibodies for tTG identified tTG-L as the predom-
inant form. In cortex, tTG-L protein expression peaked five
days after injury and remained elevated at least two weeks
after injury. tTG-L protein expression in the hippocampus
also peaked five days after injury, but the degree of induction
was more modest. tTG-L protein induction was supported by
northern blot and semiquantitative PCR transcript analysis.
The relatively delayed response of tTG to TBI suggests that it
is not a major contributor to the more acute pathophysio-
logical events such as those mediated by activation of
calcium-dependent proteases. The contribution of these more
delayed changes in tTG to more prolonged mechanisms of
TBI recovery remained to be examined.
tTG-S expression was more difficult to analyze, since
tTG-S protein was identified with only one of the two
antitTG antibodies and tTG-S protein was less abundant than
tTG-L protein. Although northern blot analysis detected
tTG-S transcript three days after injury, tTG-S mRNA was
undetectable in sham animals and at later time points after
injury. Semi-quantitative PCR presents the most compelling
evidence that tTG-S mRNA induction occurs. These studies
provide the first evidence of tTG induction in response to
traumatic CNS injury.
In a spinal cord ischemia model, over all TG activity
underwent a transient increase that declined to control levels
after one week (Fujita et al. 1995). In the superior cervical
ganglion, TG activity was increased within one hour after
axotomy and returned to baseline after 24 h (Gilad et al.
1985; Ando et al. 1993). TG activity also increased in the
vagus nerve after crush injury (Tetzlaff et al. 1988). These
previous studies measured over all TG activity and did not
measure expression of tTG protein or transcript. While the
current studies did not address tTG activity, TBI induction of
tTG activity may have been further potentiated by the
increased intracellular calcium flux consistent with traumatic
injury (Hubschmann and Nathanson 1985; Katayama et al.
1995), as tTG is a Ca
++ dependent enzyme.
The role of tTG induction in the neural response to injury
is not known; however, based on other experimental injury
models, both damaging and protective functions can be
proposed. For example, application of TG to injured optic
nerve promoted axonal regeneration and recovery of visual
evoked responses (Eitan et al. 1994). It was proposed that
the supportive effects of TG treatment were due to stabili-
zation of matrix proteins or protection of growing axons from
oligodendrocyte-mediated growth inhibition. It had been
previously shown that TG dimerizes interleukin-2 and that
IL-2 dimers were cytotoxic to cultured oligodendrocytes
(Eitan and Schwartz 1993).
Future studies of TBI-induced tTG expression will need to
examine the cell type localization of tTG induction as it
relates to the postinjury time course. This question is best
answered by immunohistochemical analysis or in situ
hybridization experiments. Also, the pathophysiology of
tTG induction bears further examination. tTG may not only
be important for subsequent cell death after traumatic injury,
but also for compensatory mechanisms of other brain
systems as they respond to the injury.
TG expression has been implicated in the cellular patho-
genesis of Alzheimer's disease (for a review see Lesort et al.
2000). Increased over all TG activity and tTG-specific
immunoreactivity have been observed in prefrontal areas of
Alzheimer's disease brains compared to controls, with no
differences observed in cerebellar expression (Johnson et al.
1997). Tau, the microtubule-associated-protein present in
neurofibrillary tangles of Alzheimer's disease, is readily
cross-linked by tTG (Dudek and Johnson 1993; Miller and
Johnson 1995; Appelt et al. 1996; Appelt and Balin 1997;
Murthy et al. 1998). TG also cross-links amyloid a-protein
in vitro, producing amyloid protein oligomers similar to
those seen in the neuritic plaques of Alzheimer's disease
(Ikura et al. 1993; Dudek and Johnson 1994; Ho et al.
1994). tTG-specific immunoreactivity has been observed in
neuritic plaques and amyloid cores from Alzheimer's disease
brain (Zhang et al. 1998).
If TG activity is pathophysiologically relevant to the
development of Alzheimer's disease, then TG induction after
traumatic brain injury may contribute to the epidemiological
observation that a subset of individuals who experience a
traumatic brain injury are at a greater risk for developing
Alzheimer's disease. Individuals with the apolipoprotein-a4
allele are at higher risk for developing Alzheimer's disease
than other genotypes (Saunders et al. 1993). When the risks
of Alzheimer's disease were examined in an elderly popu-
lation, it was found that the apolipoprotein-a4 allele
Fig. 7 Linear regression analysis of tTG-L mRNA expression in ipsi-
lateral cortex, comparing quanti®cation by PCR and by northern blot
analysis. The linear relation with 95% con®dence interval lines are
shown. Regression analysis revealed a slope of 1.01 and r
2  0.95.
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tein-a Ê4 allele combined with a history of traumatic head
injury was associated with a 10-fold increase in risk (Mayeux
et al. 1995). Subsequent studies have shown that the
frequency of apolipoprotein-a4 expression is higher in
individuals with amyloid a-protein deposition after head
injury than in head-injured individuals without amyloid
a-protein deposition (Nicoll et al. 1995). Although the
pathophysiological mechanism linking head trauma and
Alzheimer's disease is not known, it has been shown that
traumatic head injury increased levels of amyloid precursor
protein (APP) and this correlated with the presence of
activated microglia expressing IL-1 (Griffin et al. 1994;
Griffin et al. 1994; McKenzie et al. 1994; McKenzie et al.
1994). The induction of both APP and tTG by traumatic
brain injury provides a potential mechanism by which head
injury may contribute to Alzheimer's pathology. This
hypothesis awaits further in vivo and in vitro experiments.
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